Therefore, FGF23 antagonists are strong candidates for the treatment of renal anemia, iron deficiency and associated inflammation, and have the potential to attenuate Klotho deficiency. This evidence concerns the gene FGF23 and hyperinsulinemic hypoglycemia, familial, 4.